Cadmium, Metallothionein and Breast Cancer Progression

镉、金属硫蛋白与乳腺癌进展

基本信息

  • 批准号:
    7035910
  • 负责人:
  • 金额:
    $ 26.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-04-01 至 2009-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The applicant is the first to demonstrate that class 3 metallothionein, MT-3, is over expressed in a subset of human breast cancers and that over expression is associated with early breast cancers having a poor outcome. The applicant has also shown that the normal human breast has no detectable expression of MT-3 mRNA or protein. The applicant hypothesizes that the early over expression of MT-3 sequesters Zn +2 from important regulatory molecules, including p53, through the generation of apoMT and that this in turn renders the early breast cancer cell as a slow growing, chemotherapeutic resistant, genetically unstable cell destined to undergo progression. Three specific aims are proposed. The first is to demonstrate that the over expression of MT-3 can be developed as a prognostic indicator of early breast cancers destined to undergo tumor progression. The second aim is to define the mechanism underlying the observation that the MT-3 gene is transcriptionally silent in normal breast epithelial cells but transcriptionally active in a sub-set of human breast cancers. This goal will be accomplished by identifying the regions of the MT-3 promoter, the promoter elements, and the transcription factors involved in regulating MT-3 mRNA expression in breast cancer. The last aim is to define the mechanism underlying the observation that normal breast epithelial cells forced to over express the MT-3 gene, express abundant MT-3 mRNA, but no MT-3 protein. [To define the role that translation and proteolysis have in the expression of MT-3 mRNA and protein in the breast epithelial cell.] The long-term goal of this application is to elucidate the mechanism/s underlying the alterations of MT-3 gene regulation that occur in human breast cancer and to apply this knowledge to understanding the tumor biology of the breast cancer cell and to improve diagnosis, prognosis and ultimately treatment for the patient with breast cancer.
描述(由申请人提供):申请人首次证明3类金属硫蛋白MT-3在人乳腺癌亚组中过表达,并且过表达与预后不良的早期乳腺癌相关。申请人还表明,正常人乳房没有可检测到的MT-3 mRNA或蛋白质表达。申请人假设MT-3的早期过表达通过apoMT的产生将Zn +2与重要的调节分子(包括p53)隔离,并且这反过来使早期乳腺癌细胞成为缓慢生长、化疗抗性、遗传不稳定的细胞,注定要经历进展。提出了三个具体目标。第一个是证明MT-3的过度表达可以发展为注定要经历肿瘤进展的早期乳腺癌的预后指标。第二个目的是确定MT-3基因在正常乳腺上皮细胞中转录沉默但在人类乳腺癌亚组中转录活跃的观察结果的机制。这一目标将通过鉴定MT-3启动子的区域、启动子元件和参与调节乳腺癌中MT-3 mRNA表达的转录因子来实现。最后一个目的是确定观察到正常乳腺上皮细胞被迫过度表达MT-3基因,表达丰富的MT-3 mRNA,但没有MT-3蛋白的机制。[To确定翻译和蛋白水解在乳腺上皮细胞中MT-3 mRNA和蛋白表达中的作用。本申请的长期目标是阐明在人乳腺癌中发生的MT-3基因调节改变的潜在机制,并将该知识应用于理解乳腺癌细胞的肿瘤生物学,并改善乳腺癌患者的诊断、预后和最终治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARY ANN SENS其他文献

MARY ANN SENS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARY ANN SENS', 18)}}的其他基金

NORTH DAKOTA STATE CANCER REGISTRY
北达科他州癌症登记处
  • 批准号:
    8451164
  • 财政年份:
    2012
  • 资助金额:
    $ 26.92万
  • 项目类别:
NORTH DAKOTA STATE CANCER REGISTRY
北达科他州癌症登记处
  • 批准号:
    8499181
  • 财政年份:
    2012
  • 资助金额:
    $ 26.92万
  • 项目类别:
NORTH DAKOTA STATE CANCER REGISTRY
北达科他州癌症登记处
  • 批准号:
    8688184
  • 财政年份:
    2012
  • 资助金额:
    $ 26.92万
  • 项目类别:
Cadmium, Metallothionein and Breast Cancer Progression
镉、金属硫蛋白与乳腺癌进展
  • 批准号:
    6865116
  • 财政年份:
    2005
  • 资助金额:
    $ 26.92万
  • 项目类别:
Cadmium, Metallothionein and Breast Cancer Progression
镉、金属硫蛋白与乳腺癌进展
  • 批准号:
    7214615
  • 财政年份:
    2005
  • 资助金额:
    $ 26.92万
  • 项目类别:
Cadmium, Metallothionein and Breast Cancer Progression
镉、金属硫蛋白与乳腺癌进展
  • 批准号:
    7365239
  • 财政年份:
    2005
  • 资助金额:
    $ 26.92万
  • 项目类别:
AMINOGLYCOSIDE NEPHROTOXICITY AND CELLULAR TRANSPORT
氨基糖苷肾毒性和细胞转运
  • 批准号:
    3302098
  • 财政年份:
    1990
  • 资助金额:
    $ 26.92万
  • 项目类别:
AMINOGLYCOSIDE NEPHROTOXICITY AND CELLULAR TRANSPORT
氨基糖苷肾毒性和细胞转运
  • 批准号:
    3302097
  • 财政年份:
    1990
  • 资助金额:
    $ 26.92万
  • 项目类别:
AMINOGLYCOSIDE NEPHROTOXICITY AND CELLULAR TRANSPORT
氨基糖苷肾毒性和细胞转运
  • 批准号:
    3302094
  • 财政年份:
    1990
  • 资助金额:
    $ 26.92万
  • 项目类别:
DRUG-INDUCED NEPHROTOXICITY: A CELL CULTURE APPROACH
药物引起的肾毒性:细胞培养方法
  • 批准号:
    3446151
  • 财政年份:
    1985
  • 资助金额:
    $ 26.92万
  • 项目类别:

相似海外基金

Pathology of Breast Neoplasms determined by MRS
MRS 测定乳腺肿瘤的病理学
  • 批准号:
    nhmrc : 950215
  • 财政年份:
    1995
  • 资助金额:
    $ 26.92万
  • 项目类别:
    NHMRC Project Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了